Alexander M.M. Eggermont

Research interests

Publications

• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

  Nature · 2024 · https://doi.org/10.1038/s41586-024-08305-z

• The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

  Cancer Cell · 2020 · https://doi.org/10.1016/j.ccell.2020.09.001

• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1802357

• Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0217-1

• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-16-1396

• Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

  CA A Cancer Journal for Clinicians · 2017 · https://doi.org/10.3322/caac.21409

• Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

  European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.01.035

• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx108

• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

  Clinical Cancer Research · 2016 · https://doi.org/10.1158/1078-0432.ccr-16-1741

• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

  Nature Reviews Clinical Oncology · 2016 · 10.1038/nrclinonc.2016.58

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1611299

• Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2016.05.005

• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00083-2

• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.5997

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv623

• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

  Nature · 2014 · 10.1038/nature13121

• Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70012-9

• Cutaneous melanoma

  The Lancet · 2013 · https://doi.org/10.1016/s0140-6736(13)60802-8

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782

• Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2007.15.7636

• Final Version of 2009 AJCC Melanoma Staging and Classification

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.23.4799

• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61033-8

• TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility

  The Oncologist · 2006 · https://doi.org/10.1634/theoncologist.11-4-397

Current projects

No projects listed.